"http://dx.doi.org/10.1371/journal.pone.0049006" . . . "Heterozygous familial hypercholesterolemia; chemistry standardization project; international reference material; b synthesis inhibitor; apolipoprotein-a-i; double-blind; cardiovascular risk; ldl cholesterol; statin therapy; efficacy"@en . "164056" . . "8"^^ . "Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy"@en . . . "PLoS One" . . "000311234600018" . "Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated. Methods and Results: Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n = 58) were >= 18 years with LDL-C >= 7.8 mmol/L or LDL-C >= 5.1 mmol/L plus CHD disease, on maximally tolerated lipid-lowering therapy that excluded apheresis. Weekly subcutaneous injections of mipomersen 200 mg (n = 39) or placebo (n = 19) were added to lipid-lowering therapy for 26 weeks. Main outcome: percent reduction in LDL-C from baseline to 2 weeks after the last dose of treatment. Mipomersen (n = 27) reduced LDL-C by 36%, from a baseline of 7.2 mmol/L, for a mean absolute reduction of 2.6 mmol/L."@en . . "\u010Ce\u0161ka, Richard" . "Tardif, J., C." . "7" . "RIV/00064165:_____/12:13124!RIV13-MZ0-00064165" . . . "Chasan-Taber, S." . . . . "V" . "Gouni-Berthold, I." . . "RIV/00064165:_____/12:13124" . "[86F2633FE793]" . . "Wagener, G." . "Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated. Methods and Results: Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n = 58) were >= 18 years with LDL-C >= 7.8 mmol/L or LDL-C >= 5.1 mmol/L plus CHD disease, on maximally tolerated lipid-lowering therapy that excluded apheresis. Weekly subcutaneous injections of mipomersen 200 mg (n = 39) or placebo (n = 19) were added to lipid-lowering therapy for 26 weeks. Main outcome: percent reduction in LDL-C from baseline to 2 weeks after the last dose of treatment. Mipomersen (n = 27) reduced LDL-C by 36%, from a baseline of 7.2 mmol/L, for a mean absolute reduction of 2.6 mmol/L." . . "Burgess, L., J." . . "Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy" . . . . "McGowan, M., P." . "1"^^ . "11" . "Soran, H." . "1932-6203" . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy" . "10"^^ . . . "Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy"@en .